Key Drivers
- Strong Cash Position
- Ongoing Cash Burn
- Equity Dependence
AIAI Summary
SELLAS's strong cash balance removes near-term funding risk, but its $2.2B pre-revenue valuation leaves investors highly exposed to binary GPS Phase 3 and SLS009 AML data—making clinical clarity, not liquidity, the decisive catalyst for upside or sharp downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Position
- •Ongoing Cash Burn
- •Equity Dependence
SLS has ample liquidity and minimal debt, but zero revenue, persistent cash burn, equity reliance, and a $2.23B valuation make it a high-risk, fundamentally unsupported investment.
Price Behavior
Key Price Behavior Insights:
- •Sharp breakdown
- •Oversold momentum
- •Critical support
SLS remains in a bearish last-month trend after a sharp breakdown to $11.49, with oversold momentum supporting a possible bounce only if $11.29–$11.55 holds; otherwise, downside toward $10.00 is possible.
Sharp drop from about $13.49 to $11.55 after 2026-09-10
Sentiment & News
Key News Insights:
- •Share Price Surge
- •SLS009 Posters
- •Legal Investigations
SELLAS combines strong share momentum and SLS009 preclinical progress with recurring investor-law-firm investigations that may elevate risk.
Positive scientific visibility may support sentiment, but repeated legal notices could increase volatility for SLS shares
Similar Companies in Healthcare
Other companies in the same sector with AI ratings